Optimize Antibody Fragment Purification
Antibody fragments such as single domain antibodies (dAbs), antigen-binding fragments (Fab), and single chain variable fragments (scFvs) have unique properties that can make them better suited to certain therapeutic applications than full-sized monoclonal antibodies (mAbs).
Fragments are smaller than mAbs, which can allow them to more effectively reach their targets, and are often easier and less expensive to produce. However, the purification of antibody fragments isn’t as straightforward as for mAbs; fragments show wider variation in binding affinities and can be trickier to separate from impurities.
In this article, we look at some purification approaches that can help you harness the potential of antibody fragments.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Biosimilar Development? Subscribe today.